ProQR Therapeutics N.V. Ordinary Shares (PRQR) Stock Price

PRQRStock

$2.29+4.57%52W

Market Cap$323.16M

P/E—

PEG Ratio—

Div yield—

Beta0.16

PRQR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)39.73%

Price vs S&P 500 (4W)32.38%

VGM Score45.59

Book Value / Share (Quarterly)$0.40

P/TBV (Annual)5.71x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)50.45%

Cash Flow / Share (Quarterly)$-0.53

Price vs S&P 500 (YTD)0.55%

Net Profit Margin (TTM)-333.51%

EPS (TTM)$-0.50

10-Day Avg Trading Volume1.22M

EPS Excl Extra (TTM)$-0.50

Revenue Growth (5Y)11.58%

EPS (Annual)$-0.46

ROI (Annual)-64.56%

Net Profit Margin (5Y Avg)-923.85%

Cash / Share (Quarterly)$0.87

Revenue Growth QoQ (YoY)-57.12%

ROA (Last FY)-37.41%

Revenue Growth TTM (YoY)-30.51%

EBITD / Share (TTM)$-0.48

ROE (5Y Avg)-67.66%

Operating Margin (TTM)-339.31%

Cash Flow / Share (Annual)$-0.58

P/B Ratio5.88x

P/B Ratio (Quarterly)3.93x

Net Income / Employee (Annual)$-261,627

EV / Revenue (TTM)11.42x

Net Interest Coverage (TTM)-13.09x

ROA (TTM)-38.41%

EPS Incl Extra (Annual)$-0.46

Current Ratio (Annual)3.09x

Quick Ratio (Quarterly)2.39x

3-Month Avg Trading Volume0.98M

52-Week Price Return4.57%

Revenue / Employee (TTM)$84,542

Tangible BV / Share (Quarterly)$2.50

P/S Ratio (Annual)13.52x

Asset Turnover (Annual)0.14x

52-Week High$3.60

Operating Margin (5Y Avg)-899.36%

EPS Excl Extra (Annual)$-0.46

CapEx CAGR (5Y)2.09%

Tangible BV CAGR (5Y)10.74%

26-Week Price Return51.66%

Quick Ratio (Annual)3.01x

13-Week Price Return45.86%

Total Debt / Equity (Annual)0.32x

Current Ratio (Quarterly)2.48x

Enterprise Value$180.56M

Revenue / Share Growth (5Y)-3.84%

Asset Turnover (TTM)0.12x

Book Value / Share Growth (5Y)-15.36%

Revenue / Employee (Annual)$101,357

Pretax Margin (Annual)-257.94%

Cash / Share (Annual)$1.00

3-Month Return Std Dev82.77%

Net Income / Employee (TTM)$-282,154

ROE (Last FY)-85.44%

Net Interest Coverage (Annual)-21.33x

EPS Basic Excl Extra (Annual)$-0.46

P/FCF (TTM)13.26x

Receivables Turnover (TTM)27.17x

Total Debt / Equity (Quarterly)0.42x

EPS Incl Extra (TTM)$-0.50

Receivables Turnover (Annual)0.17x

ROI (TTM)-65.91%

P/S Ratio (TTM)16.21x

Pretax Margin (5Y Avg)-921.60%

Revenue / Share (Annual)$0.18

Tangible BV / Share (Annual)$2.50

Price vs S&P 500 (52W)-13.99%

Year-to-Date Return13.37%

5-Day Price Return-5.76%

EPS Normalized (Annual)$-0.46

ROA (5Y Avg)-28.35%

Net Profit Margin (Annual)-258.05%

Month-to-Date Return33.14%

Cash Flow / Share (TTM)$-0.50

EBITD / Share (Annual)$-0.45

Operating Margin (Annual)-265.77%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-49.32%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.50

P/TBV (Quarterly)5.71x

P/B Ratio (Annual)3.72x

Pretax Margin (TTM)-333.37%

Book Value / Share (Annual)$0.53

Price vs S&P 500 (13W)43.91%

Beta0.16x

P/FCF (Annual)10.96x

Revenue / Share (TTM)$0.15

ROE (TTM)-86.22%

52-Week Low$1.54

vGradeC

gGradeD

mGradeB

vgmGradeC

PRQR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.21	-$0.11	+49.54%(+$0.10)
Q1 2026	May 12, 2026	-$0.20	-$0.17	+14.63%(+$0.03)
Q4 2025	Mar 12, 2026	-$0.14	-$0.11	+21.16%(+$0.02)
Q3 2025	Nov 6, 2025	-$0.20	-$0.14	+29.08%(+$0.06)
Q2 2025	Aug 7, 2025	-$0.11	-$0.16	-49.85%(-$0.06)

PRQR Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.27

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
PRQRProQR Therapeutics N.V. Ordinary Shares	C	D	B	$2.29
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About ProQR Therapeutics N.V. Ordinary Shares

ProQR Therapeutics NV develops RNA-based therapeutics for severe genetic rare diseases, including cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The company's entire research and development effort is dedicated to discovering and advancing RNA therapeutics.

PRQR Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$0.13

Revenue estimate$5.77M

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

PRQR Insider Transactions

BuyJul 31, 2026
DE BOER DANIEL ANTON
Chief Executive Officer
Shares: 200,000Value: $353,960
BuyJul 17, 2026
FILIUS BART
Director
Shares: 150,000Value: $257,925
BuyJul 9, 2026
DE BOER DANIEL ANTON
Chief Executive Officer
Shares: 150,000Value: $261,000
BuyJul 7, 2026
DE BOER DANIEL ANTON
Chief Executive Officer
Shares: 150,000Value: $238,500
BuyJun 26, 2026
FILIUS BART
Director
Shares: 150,000Value: $231,000

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for July 2026

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$1.54

High$3.60